Business

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Financial Post · August 26, 2026 at 4:03 p.m.

VANCOUVER, BC and BOSTON, MA, Aug.

26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced multiple data presentations at the upcoming 16 th European Epilepsy Congress (EEC), taking place September 5-9, 2026, in Athens, Greece.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

More from Financial Post

Posthaste: U.S. businesses feel fresh pain from trade war with Canada, says this hot take on the economy

Conavi Medical to Showcase FDA-Cleared Hybrid Imaging System at TCT 2026

Future Health Launches Global Challenge to Move Health Innovation Towards Real-world Application

The Real Brokerage to Bring the Future of Real Estate to Life at RISE 2026

More in Business

Posthaste: U.S. businesses feel fresh pain from trade war with Canada, says this hot take on the economy

Conavi Medical to Showcase FDA-Cleared Hybrid Imaging System at TCT 2026

Future Health Launches Global Challenge to Move Health Innovation Towards Real-world Application

The Real Brokerage to Bring the Future of Real Estate to Life at RISE 2026

Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors

Midland Identifies New Gold-Bearing Boulders During the First Phase of Its 2026 Exploration Program on the Caniapisc Au Project